A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA positive late malignant solid tumors, and explore the applicable dose regimen for phase II clinical trials.

Trial Details

NCT ID
NCT06043466
Phase
PHASE1
Sponsor
Chongqing Precision Biotech Co., Ltd
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • CEA-targeted CAR-T cells
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Age ≥18 years old, male or female;
  • Patients with advanced malignant solid tumors confirmed by histology or pathology, including colorectal cancer, esophageal cancer, gastric cancer, …
  • Progression or intolerance occurs after receiving systematic standard therapy according to guidelines,(systemic therapy including but not limited t…
  • Advanced colorectal cancer: progression or intolerance or inadequacy after third-line standard therapy including cetuximab ± Irinotecan/regorafenib…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →